A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb® drug candidates with improved properties and multi-target mechanisms of action. We advance these candidates into clinical-stage development, where we are conducting Phase 1 and Phase 2 studies for a broad portfolio of programs, to determine which programs to advance into later stages of development and potentially commercialization, which programs we partner to optimize development, and which programs we discontinue. Our approach to protein design includes engineering Fc domains, the parts of antibodies that interact with multiple segments of the immune system and control antibody structure.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 126M | 126M | - | 175M | 165M | 275M |
| Net Income | -92M | -92M | -233M | -133M | -55M | 83M |
| EPS | $-1.24 | $-1.24 | $-3.58 | $-2.20 | $-0.93 | $1.37 |
| Free Cash Flow | -138M | -138M | -208M | -96M | -14M | -30M |
| ROIC | -18.2% | -12.2% | -28.8% | -17.2% | -7.6% | 61.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.30 | 0.30 | 0.34 | 0.38 | 0.00 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -178M | -178M | -178M | -132M | -82M | 44M |
| Operating Margin | -141.4% | -141.4% | - | -75.8% | -50.1% | 15.9% |
| ROE | -14.5% | -14.0% | -34.7% | -19.2% | -7.6% | 12.7% |
| Shares Outstanding | 74M | 74M | 65M | 61M | 59M | 60M |
Xencor Inc passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +10.5%.
Xencor Inc (XNCR) has a 5-year average return on invested capital (ROIC) of -0.9%. This is below average and may indicate limited pricing power.
Xencor Inc (XNCR) has a market capitalization of $895M. It is classified as a small-cap stock.
Xencor Inc (XNCR) does not currently pay a regular dividend.
Xencor Inc (XNCR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Xencor Inc (XNCR) reported annual revenue of $126 million in its most recent fiscal year, based on SEC EDGAR filings.
Xencor Inc (XNCR) has a net profit margin of -73.2%. The company is currently unprofitable.
Xencor Inc (XNCR) generated $-138 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Xencor Inc (XNCR) has a debt-to-equity ratio of 0.30. This indicates a conservatively financed balance sheet.
Xencor Inc (XNCR) reported earnings per share (EPS) of $-1.24 in its most recent fiscal year.
Xencor Inc (XNCR) has a return on equity (ROE) of -14.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 14 years of financial data for Xencor Inc (XNCR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Xencor Inc (XNCR) has a book value per share of $8.57, based on its most recent annual SEC filing.